Novel HRM Assays Expedite Drug Resistance Surveillance for Leprosy Research
The significant drop in leprosy worldwide is attributed to the development of antimicrobial multidrug therapy (MDT). Resistance to rifampicin — the backbone of MDT treatment — has appeared. Controlling leprosy transmission requires routine surveillance for mutations in the drug target genes before, during, and after the course of treatment. New high resolution melt (HRM) assays offer leprosy researchers a faster, more economical method to investigate resistance targets.